Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5098778 | 0.90 | CYP2C19 (0.44) | CYP2C19ALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL5105397 | 0.87 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2TDP1GAAKMT2A | |
| SCHEMBL4687256 | 0.86 | CTSK (0.38) | CYP2C19ALDH1A1KMT2AMEN1 | |
| SCHEMBL5105628 | 0.85 | ATM (0.47) | ALDH1A1SMN1; SMN2GAAATM | |
| SCHEMBL5092882 | 0.85 | POLB (0.49) | ALDH1A1SMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL5105882 | 0.84 | CTSK (0.41) | — | |
| SCHEMBL4693518 | 0.81 | CTSK (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5092592 | 0.80 | LMNA (0.36) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL5096610 | 0.79 | GAA (0.39) | ALDH1A1SMN1; SMN2GAATP53 | |
| SCHEMBL7246379 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | AKR1C3 2676/4885CYP2C19 626/4885ALDH1A1 3651/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | AKR1C3 2873/4885CYP2C19 1707/4885ALDH1A1 3117/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | AKR1C3 2676/4885CYP2C19 626/4885ALDH1A1 3651/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | AKR1C3 2676/4885CYP2C19 626/4885ALDH1A1 3651/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | AKR1C3 2676/4885CYP2C19 626/4885ALDH1A1 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.